Paws Over Profits · Research library
Librela, Solensia & anti-NGF research
Explore the scientific publications cited in our June 1, 2026 FDA Citizen Petition and research published since then. We have grouped the sources by subject so pet parents, veterinarians and journalists can go directly to the original publications.
How to read this page: Clinical trials, adverse-event analyses, commentaries, laboratory studies and regulatory documents answer different questions. A reported association or proposed mechanism does not by itself prove that a drug caused an outcome in an individual animal. Where available, each title links to the publisher or an authoritative public record.
Published after the petition
Research published after June 1, 2026
Bedinvetmab (Librela/Beransa) in dogs raises safety concerns, including rapidly progressive osteoarthritis, and warrants vigilant adverse event reporting
Reviews clinical and radiographic observations of unusual joint changes and calls for careful monitoring and reporting.
A neurotrophic withdrawal hypothesis for multisystem adverse events associated with anti-NGF therapy for canine osteoarthritis pain
Proposes a testable explanation for reported joint, neurologic and other events. The authors state that direct evidence for the mechanism in treated dogs is still lacking.
Librela and Solensia
Veterinary research and clinical commentary cited in the petition
Musculoskeletal adverse events in dogs receiving bedinvetmab (Librela)
Analyzes suspected musculoskeletal adverse-event reports and specialist-reviewed cases. Reporting associations warrant investigation; they do not establish an individual dog's cause of injury.
Commentary: Musculoskeletal adverse events in dogs receiving bedinvetmab (Librela)
Discusses the Farrell findings in light of clinical experience and prior anti-NGF joint-safety concerns.
Dysmetabolism of the nerve growth factor pathway in the aging brain plays a pivotal role in cognitive decline
Reviews NGF biology and cognitive decline. It is background on biologic plausibility, not a clinical study of Librela-treated dogs.
Emerging signs of rapidly progressive arthritic changes in dogs and cats receiving bedinvetmab and frunevetmab
Describes concerning radiographic changes observed in treated dogs and a cat; the small number of cases does not establish how often these outcomes occur.
A randomised, parallel-group clinical trial comparing bedinvetmab to meloxicam for the management of canine osteoarthritis
Compares short-term pain outcomes and adverse events in dogs receiving bedinvetmab or meloxicam. Longer-term structural safety was outside the trial's duration.
Further characterization of a potential musculoskeletal syndrome associated with bedinvetmab in dogs: results from a surgeon questionnaire
A surgeon-questionnaire presentation. The linked conference schedule confirms the presentation; it is not the full abstract or a peer-reviewed journal article.
Human anti-NGF experience
Tanezumab trials and the imaging used to monitor joint safety
Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period
Reports efficacy and adverse events in a human anti-NGF trial, including joint-safety outcomes relevant to the drug class.
Role of imaging for eligibility and safety of a-NGF clinical trials
Explains why anti-NGF trials used structured imaging to identify joint abnormalities at screening and during treatment.
Inter-reader consistency and exclusionary findings during radiographic screening for phase 3 trials of tanezumab in patients with osteoarthritis
Describes radiographic screening across three phase 3 tanezumab trials. This resolves an incomplete reference in the supplied citation list.
Nerve growth factor biology
Foundational and translational research cited in the petition
Peripheral neutralization of nerve growth factor induces immunosympathectomy and central neurodegeneration in transgenic mice
Studies effects of peripheral NGF neutralization in genetically modified mice. These findings cannot be directly generalized to treated pets.
Nerve growth factor: from the early discoveries to the potential clinical use
Surveys the functions of NGF in sensory, autonomic, central nervous, endocrine and immune systems.
Nerve growth factor receptor limits inflammation to promote remodeling and repair of osteoarthritic joints
Examines NGF-receptor activity in experimental osteoarthritis and human tissue. The title and lead author correct a mismatch in the supplied list.
Localization of nerve growth factor expression to structurally damaged cartilaginous tissues in human lumbar facet joint osteoarthritis
Finds NGF expression associated with damaged cartilage in samples of human spinal joints.
Local injections of β-NGF accelerates endochondral fracture repair by promoting cartilage to bone conversion
Tests locally administered NGF during fracture healing in mice. The title and lead author correct a mismatch in the supplied list.
From neuromodulation to bone homeostasis: therapeutic targets of nerve growth factor in skeletal diseases
Surveys NGF signaling in bone physiology, osteoarthritis and fracture repair.
Regulatory and historical context
Related sources from the citation list; these are not research studies
CVM GFI #298 (VICH GL62): Target Animal Safety Evaluation for Veterinary Monoclonal Antibody Products
Proposed recommendations for veterinary monoclonal antibody safety evaluation. The document is a draft and is not in effect.
Fort Dodge recalls ProHeart 6, citing FDA safety concerns
Historical account of a veterinary drug recall, included for regulatory context rather than as scientific evidence about Librela or Solensia.